Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666248 | 1.00 | DPP4 (0.59) | DPP4DPP8DPP7 | |
| SCHEMBL875490 | 0.97 | DPP4 (0.63) | DPP4DPP8DPP7 | |
| SCHEMBL197391 | 0.97 | DPP4 (0.63) | DPP4DPP8DPP7 | |
| SCHEMBL1436263 | 0.88 | DPP4 (0.55) | DPP4DPP8DPP7 | |
| SCHEMBL666999 | 0.88 | DPP4 (0.55) | DPP4DPP8DPP7 | |
| SCHEMBL4594315 | 0.88 | DPP4 (0.54) | DPP4DPP8DPP7 | |
| SCHEMBL665830 | 0.88 | DPP4 (0.54) | DPP4DPP8DPP7 | |
| SCHEMBL1436492 | 0.88 | DPP4 (0.55) | DPP4 | |
| SCHEMBL667336 | 0.88 | DPP4 (0.55) | DPP4 | |
| SCHEMBL4636425 | 0.87 | DPP4 (0.58) | DPP4DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772264-B2 | Salt and polymorphs of a DPPIV inhibitor | HOFFMANN-LA ROCHE INC. (US) | 2010-08-10 | — | — | US | claimed |
| JP-2008534470-A | — | — | 2008-08-28 | — | — | JP | claimed |
| EP-1888571-A2 | NEW SALT AND POLYMORPHS OF A DPP-IV INHIBITOR | F. Hoffmann-Roche AG (CH) | 2008-02-20 | — | — | EP | claimed |
| US-20060217428-A1 | Salt and polymorphs of a DPPIV inhibitor | HOFFMANN-LA ROCHE INC. | 2006-09-28 | — | — | US | claimed |
| WO-2006100181-A2 | NEW SALT AND POLYMORPHS OF A DPP-IV INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-28 | — | — | WO | claimed |
| US-7772264-B2 | Salt and polymorphs of a DPPIV inhibitor | HOFFMANN-LA ROCHE INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772264-B2 | Salt and polymorphs of a DPPIV inhibitor | HOFFMANN-LA ROCHE INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1917001-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A DPP-IV INHIBITOR | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1888571-A2 | NEW SALT AND POLYMORPHS OF A DPP-IV INHIBITOR | F. Hoffmann-Roche AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007017423-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A DPP-IV INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
| US-20060217428-A1 | Salt and polymorphs of a DPPIV inhibitor | HOFFMANN-LA ROCHE INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060217428-A1 | Salt and polymorphs of a DPPIV inhibitor | HOFFMANN-LA ROCHE INC. | 2006-09-28 | — | — | US | disclosed |
| WO-2006100181-A2 | NEW SALT AND POLYMORPHS OF A DPP-IV INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217428-A1 | Salt and polymorphs of a DPPIV inhibitor | DPP4, DPP3, DPP9 | DPP4 1/4885DPP8 6/4885DPP7 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.